COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2· 57 million people in Scotland (EAVE II): a prospective cohort …
U Agrawal, SV Katikireddi, C McCowan… - The Lancet …, 2021 - thelancet.com
Summary Background The UK COVID-19 vaccination programme has prioritised vaccination
of those at the highest risk of COVID-19 mortality and hospitalisation. The programme was …
of those at the highest risk of COVID-19 mortality and hospitalisation. The programme was …
[HTML][HTML] Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Summary Background The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19
(Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in …
(Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in …
[HTML][HTML] Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million …
U Agrawal, S Bedston, C McCowan, J Oke, L Patterson… - The Lancet, 2022 - thelancet.com
Background Current UK vaccination policy is to offer future COVID-19 booster doses to
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health …
Objective To estimate waning of covid-19 vaccine effectiveness over six months after second
dose. Design Cohort study, approved by NHS England. Setting Linked primary care …
dose. Design Cohort study, approved by NHS England. Setting Linked primary care …
[HTML][HTML] Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
Background: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca)
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …
[HTML][HTML] Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
Effectiveness of Covid-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study
P Nordström, M Ballin, A Nordström - Hospitalization, and Death …, 2021 - papers.ssrn.com
Background: Whether vaccine effectiveness against Coronavirus disease 2019 (Covid-19)
lasts longer than 6 months is unclear. Methods: A retrospective cohort study was conducted …
lasts longer than 6 months is unclear. Methods: A retrospective cohort study was conducted …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
[HTML][HTML] Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study …
SV Katikireddi, T Cerqueira-Silva, E Vasileiou… - The Lancet, 2022 - thelancet.com
Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but
whether this reflects waning or new SARS-CoV-2 variants—especially delta (B. 1.617. 2)—is …
whether this reflects waning or new SARS-CoV-2 variants—especially delta (B. 1.617. 2)—is …
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case …
Summary Background On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination
authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector …
authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector …